Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_assertion type Assertion NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_head.
- NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_assertion description "[Furthermore, combinations of PT-20210A or FVL with PAI-1 (4G/4G) were significantly more frequent in APS patients (5.8%) than in normal controls (0.5%, p=0.016).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_provenance.
- NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_assertion evidence source_evidence_literature NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_provenance.
- NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_assertion SIO_000772 11454529 NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_provenance.
- NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_assertion wasDerivedFrom befree-2016 NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_provenance.
- NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_assertion wasGeneratedBy ECO_0000203 NP323939.RAaEmMmHNyLK4EUl3ITDWYfk_UcLOlZBVkRia0bCPaX4k130_provenance.